Stock listing
Frankfurt:PX91 Filana Therapeutics, Inc. Aktie
German listing (Frankfurt) of Filana Therapeutics, Inc. · home listing NASDAQ:FLNA
Follow Filana Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · FWB:PX91
€0.571 EUR +0.035 (+6.5%)
Close on Oct 30, 2026
- Day range
- €0.571 – €0.571 EUROct 30, 2026
- Market cap
- €27.58M EURAt the close on Oct 30, 2026 · price × 48.31M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:FLNA · Home | $0.561 USD | -0.061 (-9.8%) | 544,958 | $0.630 | $0.630 | $0.560 | $0.622 | Close on Nov 2, 2026 |
| Frankfurt:PX91 | €0.571 EUR | +0.035 (+6.5%) | — | €0.571 | €0.571 | €0.571 | €0.536 | Close on Oct 30, 2026 |
- Ticker
- Frankfurt:PX91
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
Filana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient Cells
Latest news
Filana Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 7 in the last 12 months · 7 in all · newest Oct 28, 2026 · oldest 2026
Where Filana Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:FLNA · Home listing | NASDAQ | United States | USD |
| gettex:PX91 | gettex | Germany | EUR |
| LS Exchange:A2PGL8 | LS Exchange | Germany | EUR |
| BOATS:FLNA | BOATS | United States | USD |
| Lang & Schwarz:A2PGL8 | Lang & Schwarz | Germany | EUR |
| Tradegate:PX91 | Tradegate | Germany | EUR |
| BMV:FLNA | BMV | Mexico | MXN |
| Frankfurt:PX91 · This page | Frankfurt | Germany | EUR |
| Dusseldorf:PX91 | Dusseldorf | Germany | EUR |
| Hamburg:PX91 | Hamburg | Germany | EUR |
| Munich:PX91 | Munich | Germany | EUR |
| Stuttgart:PX91 | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Filana Therapeutics, Inc.